ArticleThoracic cancer2017

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

Minoru Fukuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.